BALVERSA™ (erdafitinib) for Healthcare Professionals

Balversa (erdafitinib)

Now Approved

BALVERSA™ is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has

Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA™.

Information on FDA-approved tests for the detection of FGFR genetic alterations in urothelial cancer is available at: http://www.fda.gov/CompanionDiagnostics.

This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Learn About FGFR Testing

Learn More About BALVERSA™

Please visit JanssenMSL.com and enter your ZIP code to find contact information for the Medical Science Liaison (MSL) in your area

For product-related questions, please contact Janssen Medical Information by calling 1‑800‑JANSSEN (1‑800‑526‑7736), submitting questions via www.askjanssenmedicalinformation.com, or searching www.JanssenMD.com

Prescription Information and Patient Support for BALVERSA™

BALVERSA™ is dispensed by US Bioservices specialty pharmacy. To request BALVERSA™ for your patient, please call 877‑757‑0667 or complete and fax a BALVERSA™ Referral Form.

Access Support

To help you get your patients started on BALVERSA™, the following resources may be helpful to your patients and your practice:
Sample Exception Letter Each payer follows a different process when filing exceptions and appeals. Submit an exception letter when requesting an exception for BALVERSA™.
Sample Letter of Medical Necessity Submit a letter to support the medical necessity of treatment with BALVERSA™ either with the initial claim or when requesting reconsideration of a denied claim.

For information on affordability programs that may be available for your patient, visit JanssenPrescriptionAssistance.com.

close

You are leaving the BALVERSA™ (erdafitinib) HCP website

You are being directed to a third-party website. Please note that this third-party website is not controlled by balversahcp.com or subject to our Privacy Policy.

Thank you for visiting our site.

Go to Link Cancel